Search

Your search keyword '"Attard G"' showing total 838 results
Start Over Author "Attard G"
838 results on '"Attard G"'

4. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer

Author

Sutera, P.A., Shetty, A.C., Hakansson, A., Van der Eecken, K., Song, Y., Liu, Y., Chang, J., Fonteyne, V., Mendes, A.A., Lumen, N., Delrue, L., Verbeke, S., De Man, K., Rana, Z., Hodges, T., Hamid, A., Roberts, N., Song, D.Y., Pienta, K., Ross, A.E., Feng, F., Joniau, S., Spratt, D., Gillessen, S., Attard, G., James, N.D., Lotan, T., Davicioni, E., Sweeney, C., Tran, P.T., Deek, M.P., and Ost, P.

Published
2023
Full Text
View/download PDF

5. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

Author

Chi, K.N., Sandhu, S., Smith, M.R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A.J., Small, E.J., Rathkopf, D.E., Gurney, H., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Urtishak, K., Corral, A. del, Francis, P., Kim, W., and Efstathiou, E.

Published
2023
Full Text
View/download PDF

8. Fracture-related hospitalisations in de novo advanced or metastatic hormone-sensitive prostate cancer: Secondary analysis of the STAMPEDE abiraterone acetate plus prednisone +/- enzalutamide and M1|RT phase 3 trials using health systems data

Author

Jones, C., primary, Dutey-Magni, P., additional, Murphy, L., additional, Murray, M., additional, Brown, J., additional, Mccloskey, E., additional, Parmar, M.K.B., additional, Parker, C., additional, Attard, G., additional, James, N.D., additional, Sydes, M.R., additional, Brown, L.C., additional, Clarke, N.W., additional, and Sachdeva, A., additional

Published
2024
Full Text
View/download PDF

12. Characteristics and healthcare resource utilisation (HRU) of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide (ENZ) or abiraterone acetate (AA) in England: PROCCO study

Author

Merseburger, A., primary, Faria, R., additional, Bahl, A., additional, Attard, G., additional, Snijder, R., additional, Sodatonou, H., additional, Pranzo, A., additional, Martins, K., additional, Rozario, N., additional, Flach, C., additional, Ridsdale-Smith, J., additional, and Chilelli, A., additional

Published
2023
Full Text
View/download PDF

13. Transcriptomic Heterogeneity of Metastatic Disease Timing within Metastatic Castration-Sensitive Prostate Cancer

Author

Sutera, P., primary, Shetty, A., additional, Hakansson, A., additional, Van der Eecken, K., additional, Song, Y., additional, Liu, Y., additional, Fonteyne, V., additional, Verbeke, S., additional, Song, D., additional, Ross, A.E., additional, Feng, F.Y., additional, Gillessen, S., additional, Attard, G., additional, James, N., additional, Lotan, T.L., additional, Davicioni, E., additional, Sweeney, C., additional, Tran, P.T., additional, Deek, M.P., additional, and Ost, P., additional

Published
2023
Full Text
View/download PDF

14. Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer

Author

Sutera, P., primary, Shetty, A., additional, Song, Y., additional, Hodges, T., additional, Hoang, T., additional, Rana, Z.H., additional, Pienta, K., additional, Feng, F.Y., additional, Song, D., additional, DeWeese, T.L., additional, Gillessen, S., additional, James, N., additional, Attard, G., additional, Deek, M.P., additional, and Tran, P.T., additional

Published
2023
Full Text
View/download PDF

15. Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer

Author

Phillips, R., primary, Proudfoot, J., additional, Davicioni, E., additional, Spratt, D.E., additional, Feng, F.Y., additional, Simko, J., additional, Den, R.B., additional, Pollack, A., additional, Rosenthal, S.A., additional, Sartor, O., additional, Sweeney, C., additional, Attard, G., additional, Patel, S.I., additional, Hall, W.A., additional, Efstathiou, J.A., additional, Shah, A.B., additional, Hoffman, K.E., additional, Pugh, S., additional, Sandler, H.M., additional, and Tran, P.T., additional

Published
2023
Full Text
View/download PDF

16. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse

Author

Taavitsainen, S., Engedal, N., Cao, S., Handle, F., Erickson, A., Prekovic, S., Wetterskog, D., Tolonen, T., Vuorinen, E. M., Kiviaho, A., Nätkin, R., Häkkinen, T., Devlies, W., Henttinen, S., Kaarijärvi, R., Lahnalampi, M., Kaljunen, H., Nowakowska, K., Syvälä, H., Bläuer, M., Cremaschi, P., Claessens, F., Visakorpi, T., Tammela, T. L. J., Murtola, T., Granberg, K. J., Lamb, A. D., Ketola, K., Mills, I. G., Attard, G., Wang, W., Nykter, M., and Urbanucci, A.

Published
2021
Full Text
View/download PDF

18. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Author

Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones, R.J., Langley, R.E., MacNair, A., Malik, Z., Mason, M.D., Matheson, D., Millman, R., Parker, C.C., Ritchie, A.W.S., Rush, H., Russell, J.M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O'Sullivan, J.M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N.N., Simms, M., Tanguay, J.S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M.R., Parmar, M.K.B., and James, N.D.

Published
2019
Full Text
View/download PDF

19. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Author

Sydes, M.R., Spears, M.R., Mason, M.D., Clarke, N.W., Dearnaley, D.P., de Bono, J.S., Attard, G., Chowdhury, S., Cross, W., Gillessen, S., Malik, Z.I., Jones, R., Parker, C.C., Ritchie, A.W.S., Russell, J.M., Millman, R., Matheson, D., Amos, C., Gilson, C., Birtle, A., Brock, S., Capaldi, L., Chakraborti, P., Choudhury, A., Evans, L., Ford, D., Gale, J., Gibbs, S., Gilbert, D.C., Hughes, R., McLaren, D., Lester, J.F., Nikapota, A., O’Sullivan, J., Parikh, O., Peedell, C., Protheroe, A., Rudman, S.M., Shaffer, R., Sheehan, D., Simms, M., Srihari, N., Strebel, R., Sundar, S., Tolan, S., Tsang, D., Varughese, M., Wagstaff, J., Parmar, M.K.B., and James, N.D.

Published
2018
Full Text
View/download PDF

20. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters

Author

Linch, M., Goh, G., Hiley, C., Shanmugabavan, Y., McGranahan, N., Rowan, A., Wong, Y.N.S., King, H., Furness, A., Freeman, A., Linares, J., Akarca, A., Herrero, J., Rosenthal, R., Harder, N., Schmidt, G., Wilson, G.A., Birkbak, N.J., Mitter, R., Dentro, S., Cathcart, P., Arya, M., Johnston, E., Scott, R., Hung, M., Emberton, M., Attard, G., Szallasi, Z., Punwani, S., Quezada, S.A., Marafioti, T., Gerlinger, M., Ahmed, H.U., and Swanton, C.

Published
2017
Full Text
View/download PDF

22. ReIMAGINE Prostate Cancer Risk: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood, urine and imaging for biomarker analyses

Author

Ahmed, H.U., primary, Frangou, E., additional, Marsden, T., additional, Moore, C., additional, Shonit, P., additional, Singh, P., additional, Brew-Graves, C., additional, Clow, R., additional, Freeman, A., additional, Hadley, J., additional, Rawlins, F., additional, Santaolalla, A., additional, Rodriguez-Justo, M., additional, Syer, T., additional, Tuck, S., additional, Wingate, A., additional, Van Hemelrijk, M., additional, Attard, G., additional, Brown, L., additional, and Emberton, M., additional

Published
2023
Full Text
View/download PDF

23. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Author

Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., and Tombal, B.

Published
2015
Full Text
View/download PDF

26. Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes

Author

Loveday, C., primary, Garrett, A., additional, Law, P., additional, Hanks, S., additional, Poyastro-Pearson, E., additional, Adlard, J.W., additional, Barwell, J., additional, Berg, J., additional, Brady, A.F., additional, Brewer, C., additional, Chapman, C., additional, Cook, J., additional, Davidson, R., additional, Donaldson, A., additional, Douglas, F., additional, Greenhalgh, L., additional, Henderson, A., additional, Izatt, L., additional, Kumar, A., additional, Lalloo, F., additional, Miedzybrodzka, Z., additional, Morrison, P.J., additional, Paterson, J., additional, Porteous, M., additional, Rogers, M.T., additional, Walker, L., additional, Eccles, D., additional, Evans, D.G., additional, Snape, K., additional, Hanson, H., additional, Houlston, R.S., additional, Turnbull, C., additional, Ardern-Jones, A., additional, Adlard, J., additional, Ahmed, M., additional, Attard, G., additional, Bailey, K., additional, Bancroft, E., additional, Bardsley, C., additional, Barton, D., additional, Bartlett, M., additional, Baxter, L., additional, Belk, R., additional, Bernhard, B., additional, Bishop, T., additional, Boyes, L., additional, Bradshaw, N., additional, Brant, S., additional, Brice, G., additional, Bromilow, G., additional, Brooks, C., additional, Bruce, A., additional, Bulman, B., additional, Burgess, L., additional, Campbell, J., additional, Canham, N., additional, Castle, B., additional, Cetnarskyj, R., additional, Claber, O., additional, Coates, N., additional, Cole, T., additional, Collins, A., additional, Coulson, S., additional, Crawford, G., additional, Cruger, D., additional, Cummings, C., additional, D’Mello, L., additional, Day, L., additional, Dell, B., additional, Dolling, C., additional, Dorkins, H., additional, Downing, S., additional, Drummond, S., additional, Dubras, C., additional, Dunlop, J., additional, Durrell, S., additional, Eddy, C., additional, Edwards, M., additional, Edwards, E., additional, Edwardson, J., additional, Eeles, R., additional, Ellis, I., additional, Elmslie, F., additional, Evans, G., additional, Gibbons, B., additional, Gardiner, C., additional, Ghali, N., additional, Giblin, C., additional, Gibson, S., additional, Goff, S., additional, Goodman, S., additional, Goudie, D., additional, Grier, J., additional, Gregory, H., additional, Halliday, S., additional, Hardy, R., additional, Hartigan, C., additional, Heaton, T., additional, Higgins, C., additional, Hodgson, S., additional, Homfray, T., additional, Horrigan, D., additional, Houghton, C., additional, Hughes, L., additional, Hunt, V., additional, Irvine, L., additional, Jacobs, C., additional, James, S., additional, James, M., additional, Jeffers, L., additional, Jobson, I., additional, Jones, W., additional, Kennedy, M.J., additional, Kenwrick, S., additional, Kightley, C., additional, Kirk, C., additional, Kirk, E., additional, Kivuva, E., additional, Kohut, K., additional, Kosicka-Slawinska, M., additional, Kulkarni, A., additional, Lambord, N., additional, Langman, C., additional, Leonard, P., additional, Levene, S., additional, Locker, S., additional, Logan, P., additional, Longmuir, M., additional, Lucassen, A., additional, Lyus, V., additional, Magee, A., additional, Male, A., additional, Mansour, S., additional, McBride, D., additional, McCann, E., additional, McConnell, V., additional, McEntagart, M., additional, McKeown, C., additional, McLeish, L., additional, McLeod, D., additional, Melville, A., additional, Mercer, L., additional, Mercer, C., additional, Mitra, A., additional, Murday, V., additional, Murray, A., additional, Myhill, K., additional, Myring, J., additional, O'Hara, E., additional, Pearson, P., additional, Pichert, G., additional, Platt, K., additional, Pottinger, C., additional, Price, S., additional, Protheroe, L., additional, Pugh, S., additional, Quarrell, O., additional, Randhawa, K., additional, Riddick, C., additional, Robertson, L., additional, Robinson, A., additional, Roffey-Johnson, V., additional, Rogers, M., additional, Rose, S., additional, Rowe, S., additional, Schofield, A., additional, Rahman, N., additional, Saya, S., additional, Scott, G., additional, Scott, J., additional, Searle, A., additional, Shanley, S., additional, Sharif, S., additional, Shaw, A., additional, Shaw, J., additional, Shea-Simonds, J., additional, Side, L., additional, Sillibourne, J., additional, Simon, K., additional, Simpson, S., additional, Slater, S., additional, Smalley, S., additional, Smith, K., additional, Snadden, L., additional, Soloway, J., additional, Stait, Y., additional, Stayner, B., additional, Steel, M., additional, Steel, C., additional, Stewart, H., additional, Stirling, D., additional, Thomas, M., additional, Thomas, S., additional, Tomkins, S., additional, Turner, H., additional, Vandersteen, A., additional, Wakeling, E., additional, Waldrup, F., additional, Watt, C., additional, Watts, S., additional, Webber, A., additional, Whyte, C., additional, Wiggins, J., additional, Williams, E., additional, and Winchester, L., additional

Published
2022
Full Text
View/download PDF

27. 158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study

Author

Binti Saad, M., primary, Chi, K.N., additional, Jung, W., additional, Pang, S-T., additional, Attard, G., additional, Sandhu, S.K., additional, Mason, G.E., additional, del Corral, A., additional, Wang, G., additional, Wu, D., additional, Diorio, B., additional, Lopez-Gitlitz, A., additional, and Lee, J.Y., additional

Published
2022
Full Text
View/download PDF

28. 1359MO Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE

Author

Haran, Á.M., primary, Jain, Y., additional, Hambrock, T., additional, Murphy, L.R., additional, Cook, A., additional, Brown, L.C., additional, Hoyle, A.P., additional, Sachdeva, A., additional, Ali, S.A., additional, Amos, C.L., additional, Sydes, M.R., additional, Attard, G., additional, Parmar, M.K., additional, James, N.D., additional, and Clarke, N.W., additional

Published
2022
Full Text
View/download PDF

29. LBA62 Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol

Author

Attard, G., primary, Murphy, L., additional, Clarke, N., additional, Cross, W., additional, Gillessen, S., additional, Amos, C., additional, Brawley, C., additional, Jones, R., additional, Pezaro, C., additional, Malik, Z., additional, Montazeri, A., additional, Millman, R., additional, Cook, A., additional, Gilbert, D., additional, Langley, R., additional, Parker, C., additional, Sydes, M., additional, Brown, L., additional, Parmar, M., additional, and James, N., additional

Published
2022
Full Text
View/download PDF

32. The ReIMAGINE prostate cancer risk study protocol:A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses

Author

Marsden, T, McCartan, N, Brown, L, Rodriguez-Justo, M, Syer, T, Brembilla, G, Van Hemelrijck, M, Coolen, T, Attard, G, Punwani, S, Moore, CM, Ahmed, HU, Emberton, M, ReIMAGINE Study Group, and Medical Research Council (MRC)

Subjects
Image-Guided Biopsy, Male, Multidisciplinary, General Science & Technology, Prostate, Prostatic Neoplasms, Middle Aged, ReIMAGINE Study Group, Artificial Intelligence, Risk Factors, Biomarkers, Tumor, Humans, Multiparametric Magnetic Resonance Imaging, Neoplasm Grading, Ultrasonography, Interventional, Aged
Abstract

Introduction The ReIMAGINE Consortium was conceived to develop risk-stratification models that might incorporate the full range of novel prostate cancer (PCa) diagnostics (both commercial and academic). Methods ReIMAGINE Risk is an ethics approved (19/LO/1128) multicentre, prospective, observational cohort study which will recruit 1000 treatment-naive men undergoing a multi-parametric MRI (mpMRI) due to an elevated PSA (≤20ng/ml) or abnormal prostate examination who subsequently had a suspicious mpMRI (score≥3, stage ≤T3bN0M0). Primary outcomes include the detection of ≥Gleason 7 PCa at baseline and time to clinical progression, metastasis and death. Baseline blood, urine, and biopsy cores for fresh prostate tissue samples (2 targeted and 1 non-targeted) will be biobanked for future analysis. High-resolution scanning of pathology whole-slide imaging and MRI-DICOM images will be collected. Consortium partners will be granted access to data and biobanks to develop and validate biomarkers using correlation to mpMRI, biopsy-based disease status and long-term clinical outcomes. Results Recruitment began in September 2019(n = 533). A first site opened in September 2019 (n = 296), a second in November 2019 (n = 210) and a third in December 2020 (n = 27). Acceptance to the study has been 65% and a mean of 36.5ml(SD+/-10.0), 12.9ml(SD+/-3.7) and 2.8ml(SD+/-0.7) urine, plasma and serum donated for research, respectively. There are currently 4 academic and 15 commercial partners spanning imaging (~9 radiomics, artificial intelligence/machine learning), fluidic (~3 blood-based and ~2urine-based) and tissue-based (~1) biomarkers. Conclusion The consortium will develop, or adjust, risk models for PCa, and provide a platform for evaluating the role of novel diagnostics in the era of pre-biopsy MRI and targeted biopsy.

Published
2022

33. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A.

Subjects
education
Abstract

Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: To present the voting results from APCCC 2021. Design, setting, and participants: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making. © 2022 The Author(s)

Published
2022

34. Corrigendum to 'What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021' [Eur Urol 82(1):6–11] (European Urology (2022) 82(1) (6–11), (S0302283822016505), (10.1016/j.eururo.2022.02.010))

Author

Turco, F. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C. Clarke, N. Davis, I.D. de Bono, J. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ekeke, O.N. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Gillessen, S. Omlin, A.

Abstract

The authors regret that Axel Heidenreich was added to the author list in error. The author list is now corrected as above, however the affiliations of remaining authors have been retained. The authors would like to apologise for any inconvenience caused. © 2022 The Author(s)

Published
2022

37. Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”

Author

Perez-Navarro, E., primary, Conteduca, V., additional, González-del-Alba, A., additional, Mellado, B., additional, Cremaschi, P., additional, Fernandez-Calvo, O., additional, Méndez-Vidal, M.J., additional, Climent, M.A., additional, Duran, I., additional, Font, A., additional, Fernandez-Perez, M.P., additional, Martínez, A., additional, López-Andreo, M.J., additional, Attard, G., additional, Castellano, D., additional, Grande, E., additional, de Giorgi, U., additional, Botia, J.A., additional, Palma Méndez, J.T., additional, and Gonzalez-Billalabeitia, E., additional

Published
2022
Full Text
View/download PDF

38. Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics

Author

Sutera, P., primary, Van der Eecken, K., additional, Kishan, A.U., additional, Hamid, A., additional, Grist, E., additional, Attard, G., additional, Lotan, T.L., additional, Mendes, A., additional, Sweeney, C., additional, Paller, C., additional, Carducci, M., additional, Ross, A.E., additional, Pienta, K., additional, Feng, F.Y., additional, Eisenberger, M., additional, Antonarakis, E.S., additional, Ost, P., additional, Tran, P.T., additional, and Deek, M.P., additional

Published
2021
Full Text
View/download PDF

43. 650TiP PARADIGM: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer (mPCa)

Author

Jayaram, A.K., primary, Reid, A., additional, Wheeler, G., additional, Alifrangis, C., additional, O'Dwyer, J., additional, Jones, R., additional, Pezaro, C., additional, Pintus, E., additional, Staffurth, J., additional, Crabb, S., additional, Sidhu, H., additional, Smith, K., additional, Brock, S., additional, Rodwell, S., additional, Wingate, A., additional, Zakka, L., additional, Chiwewe, M., additional, Cartwright, H., additional, White, L., additional, and Attard, G., additional

Published
2021
Full Text
View/download PDF

44. 584P Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)

Author

Oudard, S.M., primary, Bevans, K.B., additional, Attard, G., additional, Efstathiou, E., additional, Flaig, T.W., additional, Franke, F.A., additional, Goodman, O.B., additional, De Giorgi, U., additional, Pieczonka, C.M., additional, Yeruva, K., additional, De Porre, P., additional, Brookman-May, S.D., additional, Dibaj, S., additional, Wu, D., additional, Mundle, S.D., additional, McCarthy, S., additional, Steuber, T., additional, Suzuki, H., additional, Rathkopf, D.E., additional, and Saad, F., additional

Published
2021
Full Text
View/download PDF

45. 583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide

Author

Conteduca, V., primary, Scarpi, E., additional, Wetterskog, D., additional, Brighi, N., additional, Schepisi, G., additional, Romanel, A., additional, Casadei, C., additional, Lolli, C., additional, Gurioli, G., additional, Toma, I., additional, Poti, G., additional, Farolfi, A., additional, Demichelis, F., additional, Attard, G., additional, and De Giorgi, U., additional

Published
2021
Full Text
View/download PDF

46. LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol

Author

Attard, G., primary, Brown, L.C., additional, Clarke, N., additional, Murphy, L., additional, Cross, W., additional, Jones, R., additional, Gillessen, S., additional, Russell, J.M., additional, Cook, A., additional, Bowen, J., additional, Lydon, A., additional, Pedley, I.D., additional, Parikh, O., additional, Chowdhury, S., additional, Malik, Z., additional, Matheson, D., additional, Parker, C., additional, Sydes, M.R., additional, Parmar, M.K., additional, and James, N.D., additional

Published
2021
Full Text
View/download PDF

47. 589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)

Author

Perez Navarro, E., primary, Conteduca, V., additional, Gonzalez del Alba, A., additional, Mellado, B., additional, Cremaschi, P., additional, Fernandez Calvo, O., additional, Mendez Vidal, M.J., additional, Climent Duran, M.A., additional, Duran, I., additional, Gallardo Diaz, E., additional, Vazquez, S., additional, Font Pous, A., additional, Gurioli, G., additional, Martínez, A., additional, López Andreo, M.J., additional, Attard, G., additional, Castellano Gauna, D., additional, Grande, E., additional, Giorgi, U., additional, and Gonzalez Billalabeitia, E., additional

Published
2021
Full Text
View/download PDF

50. LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

Author

Chi, K.N.N., Castro, E., Attard, G., Smith, M.R., Sandhu, S.K., Efstathiou, E., Roubaud, G., Small, E.J.J., Gomes, A.J.P.D.S., Rathkopf, D., Saad, M., Gurney, H.P., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Lopez-Gitlitz, A., Kim, W., and Olmos, D.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results